메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Ahn Young Eun (Department of Internal Medicine Korea University College of Medicine Seoul Korea) Suh Sang Jun (Department of Internal Medicine Korea University College of Medicine Seoul Korea) Yim Hyung Joon (Department of Internal Medicine Korea University College of Medicine Seoul Korea) Seo Yeon Seok (Department of Internal Medicine Korea University College of Medicine Seoul Korea) Yoon Eileen L. (Department of Internal Medicine Inje University College of Medicine Seoul Korea) Kim Tae Hyung (Department of Internal Medicine Korea University College of Medicine Seoul Korea) Lee Young Sun (Department of Internal Medicine Korea University College of Medicine Seoul Korea) Yim Sun Young (Department of Internal Medicine Korea University College of Medicine Seoul Korea) Kim Hae Rim (Department of Internal Medicine Korea University College of Medicine Seoul Korea) Kang Seong Hee (Department of Internal Medicine Yonsei University Wonju College of Medicine Wonju Korea) Jung Young Kul (Department of Internal Medicine Korea University College of Medicine Seoul Korea) Kim Ji Hoon (Department of Internal Medicine Korea University College of Medicine Seoul Korea) Yeon Jong Eun (Department of Internal Medicine Korea University College of Medicine Seoul Korea) Um Soon Ho (Department of Internal Medicine Korea University College of Medicine Seoul Korea) Byun Kwan Soo (Department of Internal Medicine Korea University College of Medicine Seoul Korea)
저널정보
거트앤리버 발행위원회 Gut and Liver Gut and Liver 제15권 제2호
발행연도
2021.1
수록면
284 - 294 (11page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background/Aims: Sorafenib is the first approved systemic treatment for advanced hepatocellular carcinoma (HCC). However, its clinical utility is limited, especially in Asian countries. Several reports have suggested the survival benefits of hepatic arterial infusion chemotherapy (HAIC) for advanced HCC with main portal vein tumor thrombosis (PVTT). This study aimed to compare the efficacy of sorafenib-based therapy with that of HAIC-based therapy for advanced HCC with main PVTT. Methods: Advanced HCC patients with main PVTT treated with sorafenib or HAIC between 2008 and 2016 at Korea University Medical Center were included. We evaluated overall survival (OS), time-to-progression (TTP), and the disease control rate (DCR). Results: Seventy-three patients were treated with sorafenib (n=35) or HAIC (n=38). Baseline characteristics were not significantly different between groups, except the presence of solid organ metastasis (46% vs 5.3%, p<0.001). The median OS time was not significantly different between the groups (6.4 months vs 10.0 months, p=0.139). TTP was longer in the HAIC group than in the sorafenib group (2.1 months vs 6.2 months, p=0.006). The DCR was also better in the HAIC group than in the sorafenib group (37% vs 76%, p=0.001). Subgroup analysis, which excluded patients with extrahepatic solid organ metastasis, showed the same trends for the median OS time (8.8 months vs 11.1 months, p=0.097), TTP (1.9 months vs 6.0 months, p<0.001), and DCR (53% vs 81%, p=0.030). Conclusions: HAIC-based therapy may be an alternative to sorafenib for advanced HCC with main PVTT by providing longer TTP and a better DCR.

목차

등록된 정보가 없습니다.

참고문헌 (33)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0